<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pbio</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosbiol</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0030285</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Science Policy</subject>
          <subject>Pharmacology</subject>
          <subject>Public Health and Epidemiology</subject>
          <subject>Non-Clinical Medicine/Health Economics</subject>
          <subject>Non-Clinical Medicine/Health Policy</subject>
          <subject>Public Health and Epidemiology</subject>
          <subject>Public Health and Epidemiology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Drugs and adverse drug reactions</subject>
          <subject>Health Policy</subject>
          <subject>Patients</subject>
          <subject>Public Health</subject>
          <subject>Regulation</subject>
        </subj-group>
      </article-categories><title-group><article-title>Author's Reply</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Kravitz</surname>
            <given-names>Richard L</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><aff id="aff1">
				<label>1</label>
				
				<addr-line>University of California Davis, Davis, California, United States of America</addr-line>
				
			</aff><author-notes>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">rlkravitz@ucdavis.edu</email></corresp>
      <fn fn-type="conflict" id="n3">
        <p>
					 The author has declared that no competing interests exist.
				</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>6</month>
        <year>2006</year>
      </pub-date><pub-date pub-type="epub">
        <day>27</day>
        <month>6</month>
        <year>2006</year>
      </pub-date><volume>3</volume><issue>6</issue><elocation-id>e285</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2006</copyright-year><copyright-holder>Richard L. Kravitz</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><related-article page="e145" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030145" xlink:title="debate" xlink:type="simple">
				<article-title>What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?</article-title>
			</related-article><related-article page="e286" related-article-type="companion" vol="3" xlink:href="info:doi/10.1371/journal.pmed.0030286" xlink:title="correspondence" xlink:type="simple">
				<article-title>Merck's Actions Surrounding Vioxx</article-title>
			</related-article><funding-group><funding-statement>
					The author received no specific funding for this article.
				</funding-statement></funding-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>In my section of the 
				<italic>PLoS Medicine</italic> Debate entitled “What Are the Public Health Effects of Direct-to-Consumer Drug Advertising?” [<xref ref-type="bibr" rid="pmed-0030285-b1">1</xref>], I noted that a two-year moratorium on direct-to-consumer (DTC) advertising of new drugs could “avoid another Vioxx tragedy, in which drug marketing got well ahead of the science.” Contrary to Michael Heinley's complaint [<xref ref-type="bibr" rid="pmed-0030285-b2">2</xref>], I did not suggest that Merck acted improperly. That is a matter for the courts to decide. My only point was that obtaining more information on the risk:benefit ratio of Vioxx prior to mass marketing would have resulted in more informed prescribing.
			</p>
      <p>From the time of its approval on May 21, 1999, until its voluntary withdrawal on September 30, 2004, Vioxx was prescribed to more than 80 million patients [<xref ref-type="bibr" rid="pmed-0030285-b3">3</xref>]. During much of that time, Merck conducted a vigorous and highly successful DTC marketing campaign. Whatever one believes about early signals of excess cardiovascular risk, by 2004 the results of the APPROVe trial had convinced everyone, including Merck, that Vioxx represented a potential threat to public health [<xref ref-type="bibr" rid="pmed-0030285-b4">4</xref>,
				<xref ref-type="bibr" rid="pmed-0030285-b5">5</xref>]. In the meantime, hundreds of thousands of patients sought and received Vioxx prescriptions as a result of watching DTC advertisements on television, and up to 16 per 1,000 may have suffered untimely myocardial infarctions or strokes as a result [<xref ref-type="bibr" rid="pmed-0030285-b3">3</xref>]. If there had been a DTC advertising moratorium in place beginning in 1999, the science of adverse-event monitoring might have had a fighting chance to catch up.
			</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0030285-b1">
        <label>1</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Almasi</surname>
              <given-names>EA</given-names>
            </name>
            <name name-style="western">
              <surname>Stafford</surname>
              <given-names>RS</given-names>
            </name>
            <name name-style="western">
              <surname>Kravitz</surname>
              <given-names>RL</given-names>
            </name>
            <name name-style="western">
              <surname>Mansfield</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>What are the public health effects of direct-to-consumer drug advertising?</article-title>
          <source>PLoS Med</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>e145</fpage>
          <comment>doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030145" xlink:type="simple">10.1371/journal.pmed.0030145</ext-link></comment>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030285-b2">
        <label>2</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Heinley</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Merck's actions surrounding Vioxx.</article-title>
          <source>PLoS Med</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>e286</fpage>
          <comment>doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0030286" xlink:type="simple">10.1371/journal.pmed.0030286</ext-link></comment>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030285-b3">
        <label>3</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Topol</surname>
              <given-names>EJ</given-names>
            </name>
          </person-group>
          <article-title>Failing the public health—Rofecoxib, Merck, and the FDA.</article-title>
          <source>New Engl J Med</source>
          <year>2004</year>
          <volume>351</volume>
          <fpage>1707</fpage>
          <lpage>1709</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030285-b4">
        <label>4</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <person-group person-group-type="author">
            <name name-style="western">
              <surname>Hampton</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Experts point to lessons learned from controversy over rofecoxib safety.</article-title>
          <source>JAMA</source>
          <year>2005</year>
          <volume>293</volume>
          <fpage>413</fpage>
          <lpage>424</lpage>
        </nlm-citation>
      </ref>
      <ref id="pmed-0030285-b5">
        <label>5</label>
        <nlm-citation publication-type="journal" xlink:type="simple">
          <collab xlink:type="simple">United States Food and Drug Administration</collab>
          <article-title>Vioxx (rofecoxib) questions and answers.</article-title>
          <year>2004</year>
          <comment>Available: 
							<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/cder/drug/infopage/vioxx/vioxxQA.htm" xlink:type="simple">http://www.fda.gov/cder/drug/infopage/vioxx/vioxxQA.htm</ext-link>. Accessed 13 May 2006</comment>
        </nlm-citation>
      </ref>
    </ref-list>
    
  </back>
</article>